Clinical Trial

Angelman Syndrome Study

Phase 1 study
Testing the safety, tolerability, and efficacy of NNZ-2591

Neuren Pharmaceuticals

NNZ-2591 is an investigational oral medicine which aims to improve the impaired connections and signaling between brain cells.

Participant Requirements

Below is a list of inclusion criteria.
See the full list of eligibility criteria on the clinical trials website.

  • Have a diagnosis of Angelman syndrome
  • Between 3-17 years old
  • Be able to swallow a liquid medication
  • Participate for approximately 19 weeks with a combination of in-clinic, remote and telehealth consultations.

Locations & Contacts

Brisbane Queensland
Children’s Health Queensland Hospital and Health Service
Honey Heussler |  (07) 30697532

Melbourne Victoria
Austin Hospital
Prof Ingrid Scheffer  |  (03) 9035 7361

Sydney, NSW
Sydney Children’s Hospital, Randwick
Dr Alexandra Johnson  |  (02) 93821549

More Information and Screening Enrollment

Find more information on the Angelman Syndrome Study website.

More details on